Cardlytics, Inc. (CDLX) Stock Price & Analysis

Cardlytics, Inc. (CDLX) closed at USD 1.87 on Thursday, October 22, 2026, up 3.31% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 1.81; the Oct 22, 2026 session ranged USD 1.76–1.89 on volume of 35,953 shares. Market capitalization is $11.01M, with a 52-week range of USD 1.67–21.7 (NGM). Source: Nexqual, retrieved October 23, 2026 at 11:03 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CDLX.md

Key facts (CDLX)

• Last four reported quarters (through Jun 30, 2026): revenue $179M, net income -$100M (-55.9% margin), free cash flow $463K (SEC filings).
• 1 of 80 tracked superinvestors hold CDLX (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
• Insider open-market sales, last ~7 months: 5 Form 4 filings, $264K; 5 not under a Rule 10b5-1 plan ($264K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $129K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Sell (mean 3.50 on a 1–5 scale) (4 analysts), mean target USD 6 (range 4–10).
• Total return with dividends: 1Y -91.0% vs S&P 500 +14.9%; 5Y -99.8% vs S&P 500 +80.3%.
• Next earnings: 2026-11-05, EPS estimate USD -1.04, revenue estimate $37.1M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CDLX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CDLX)

P/S 0.1x · EV/Sales 1.0x · P/FCF 23.8x · FCF yield 4.20% · Earnings yield -910.64% · Net debt $173M · EV $184M

Superinvestors (SEC 13F-HR, Q2 2026) (CDLX)

1 of 80 tracked investors hold CDLX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (CDLX)

0 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (CDLX)

1 purchase, $129K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (CDLX)

Consensus Sell (mean 3.50 on a 1–5 scale), 4 analysts; mean target USD 6 (low 4, high 10).

Total return (dividends reinvested) (CDLX)

CDLX revenue by business segment (quarter ended Sep 30, 2025)

CDLX revenue by product line (quarter ended Jun 30, 2026)

CDLX revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

CDLX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 4, 2026.

Companies that name CDLX in their SEC reports

CDLX customer concentration

In the period ended Dec 31, 2025, a single direct customer accounted for 20% of revenue, per the company's 10-K filed Mar 4, 2026. The company does not name it.

CDLX company outlook (results filed Aug 5, 2026)

• “Cautionary Language Concerning Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the " safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements related to building long-term value for shareholders and our financial guidance for the third quarter of 2026.”

Quoted word-for-word from the SEC 8-K results press release.

CDLX analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 11:03 UTC)

Technical Analysis (CDLX)

Nexqual's technical model rates CDLX "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 11:03 UTC.

Analyst Ratings (CDLX)

Wall Street analysts rate CDLX "Sell" based on 4 analysts, with a mean price target of USD 6 (range USD 4–10), per Nexqual as of October 23, 2026 at 11:03 UTC.

Earnings (CDLX)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 11:03 UTC.

Financials & Fundamentals (CDLX)

Source: Nexqual, October 23, 2026 at 11:03 UTC.

Financial Health Score (CDLX)

Nexqual rates Cardlytics, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 11:03 UTC.

Ownership (CDLX)

Source: Nexqual, October 23, 2026 at 11:03 UTC.

Leadership (CDLX)

Cardlytics, Inc. is led by Amit Gupta, CEO & Director, per Nexqual as of October 23, 2026 at 11:03 UTC.

Major Backers & Investors (CDLX)

Notable institutional backers of Cardlytics, Inc. include CAS Investment Partners, LLC, 683 Capital Management LLC, KPS Global Asset Management UK Limited, according to Nexqual as of October 23, 2026 at 11:03 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 11:03 UTC.

From Cardlytics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)

Key Strengths & Strategy (as disclosed to the SEC)

• Despite our efforts to protect our proprietary technology and trade secrets, unauthorized parties may attempt to misappropriate, reverse engineer or otherwise obtain and use them.
• Further, the contractual provisions that we enter into may not prevent unauthorized use or disclosure of our proprietary technology or intellectual property rights and may not provide an adequate remedy in the event of unauthorized use or disclosure of our proprietary technology or intellectual property rights.
• By serving these marketers at scale, we have developed deep insight into consumer behavior, which has allowed us to optimize how we reach and influence likely buyers. •Powerful, Self-Reinforcing Network Effects.
• Our targeting capabilities allow marketers to tailor their campaigns to align with their marketing strategies. •Proprietary Technology Architecture and Advanced Analytics Capabilities.

Partnerships

• Our relationship with Bank of America is governed by a General Services Agreement pursuant to which we provide Bank of America with access to the Cardlytics platform and certain other related services, and a related Statement of Work (collectively, the "GSA"), which grants Bank of America the right to use the software underlying the Cardlytics platform.
• Since we are able to measure the impact marketing campaigns have on in-store and online sales, marketers can use our data capabilities to optimize their advertising efforts with new or increased investment in the Cardlytics platform.

Legal & Regulatory Risks (Item 1A, quoted)

• The regulatory framework for online services and data privacy and security issues worldwide can vary substantially from jurisdiction to jurisdiction, is rapidly evolving and is likely to remain uncertain for the foreseeable future.
• We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations.
• Failure to protect our proprietary technology and intellectual property rights could substantially harm our business, financial condition and operating results.
• Our use of open-source software could negatively affect our ability to sell our solutions and subject us to possible litigation.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 11:03 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt